Equity Overview
Price & Market Data
Price: $5.09
Daily Change: +$0.97 / 19.06%
Daily Range: $3.92 - $5.12
Market Cap: $1,265,576,320
Daily Volume: 8,412,596
Performance Metrics
1 Week: -5.15%
1 Month: 0.47%
3 Months: 111.0%
6 Months: 25.44%
1 Year: 53.62%
YTD: 44.71%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country:
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.